Project Grant R43AI108072

This $1,900,450 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the advanced development and testing of a hexavalent adjuvanted influenza vaccine platform called SNAP-FLU. The primary recipient, Pop Biotechnologies Inc., will produce and characterize the physical and chemical properties of the SNAP-FLU nanoparticle vaccine, which combines recombinant influenza...

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is focused on developing nanoparticle adjuvant formulations to overcome immunodominance and stimulate broad antibody responses against influenza. The $709,236 award to the Trustees of Indiana University aims to gain mechanistic insights into how adjuvant formulation can shape B cell immunodominance and breadth of humoral...

The University of Illinois has been awarded a $649,896 Project Grant under the U.S. Department of Agriculture's Agriculture and Food Research Initiative (AFRI) program. The project aims to develop an mRNA-based influenza vaccine cocktail that can provide broad protection against diverse influenza A virus (IAV) strains, including highly pathogenic avian influenza (HPAI) H5N1 viruses. The vaccine candidate will be formulated using novel peptide-based cationic nanoparticles and will be evaluated in...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. This project aims to combine the advantages of a closely matched seasonal influenza DNA vaccine with the advantages of a universal influenza DNA vaccine to provide improved protection against both seasonal and potentially...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,082,429 Cooperative Agreement (U01AI186999) to Duke University to develop computational models that can predict the antibody response and protection provided by seasonal and universal influenza vaccines. The 5-year project, which began on December 19, 2024 and runs through November 30, 2029, aims to address the challenges of low seasonal influenza vaccine efficacy and the potential for devastating influenza pandemics....

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $586,250 Project Grant (CFDA 93.855) to the University of Massachusetts Medical School to investigate how distinct age-associated B cell subsets can protect the aged from influenza infections. The research aims to determine the potential of age-associated B cell subsets to respond to influenza infection and generate antibody-secreting cells, B cell memory, and long-lived antibody-secreting cells in various tissues. The...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $230,000 under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Scripps Research Institute. The grant, titled "Germline Targeting for Neuraminidase Broadly Neutralizing Antibodies", will support research to develop a broad-spectrum influenza vaccine by targeting the neuraminidase (NA) protein, which is recognized by broadly neutralizing antibodies. The research...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...